Oligometastatic advanced renal carcinoma
Conditions
Interventions
Group A:tirelizumab+axitinib
Group B :tirelizumab+axitinib+SBRT
Sponsors
The First Affiliated Hospital of Naval Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years; 2. Orthotopic recurrence or distant metastasis of renal cancer, histologic confirmation of clear cell renal cell carcinoma; 3. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2; 4. The number of oligo metastases is less than or equal to 5, the lesion is detectable according to the RECIST 1.1 criteria; 5. Patients with an estimated survival time > 1 year; 6. SBRT can be performed safely for at least one oligo metastasis; 7. Patients who had received systemic therapy (ineffective) or not received systemic therapy (treatment-naive); 8. All patients gave informed consent and signed a written consent form, patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures indicated in the protocol.
Exclusion criteria
Exclusion criteria: 1. Patients who had received anti–PD-1 therapy or anti–PD-L1 therapy; 2. Had contraindications for radiotherapy; 3. The lesion area has been treated with high-dose radiotherapy; 4. Had other uncured malignant tumors; 5. Patients with severe cardiovascular and cerebrovascular diseases, uncontrollable hypertension, diabetes, and renal failure; 6. Pregnant or lactating women; 7. Evidence of spinal cord compression, surgical fixation of bone injury is required to maintain stability. 8. Patients with brain metastasis; 9. Patients with autoimmune diseases requiring therapy in the past 2 years; 10. Those considered unsuitable for inclusion by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Time to local progression;Progression-free survival;Disease control rate;Security; | — |
Countries
China
Contacts
Public ContactLin-Hui Wang
The First Affiliated Hospital of Naval Medical University
Outcome results
None listed